Exact Sciences Corp
Abbott to Acquire Exact Sciences in $21 Billion Deal
Summary
Exact Sciences Corporation has entered into a definitive agreement with Abbott Laboratories for Abbott to acquire all outstanding shares of Exact Sciences for $105 per share in cash, representing a total equity value of approximately $21 billion. The transaction, which is expected to close in the second quarter of 2026, is subject to shareholder approval and regulatory clearances. Upon completion, Exact Sciences will become a subsidiary of Abbott, enhancing Abbott's position in the cancer screening and diagnostics segments.
Profitelligence Alerts
Get alerts for EXAS
Be first to know when Exact Sciences Corp files with the SEC.
Filing Categories
Advertisement
About Exact Sciences Corp
Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.
Official SEC Documents
Advertisement